Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41 by Dimitrov, DS et al.
Title
Identification and characterization of a broadly cross-reactive
HIV-1 human monoclonal antibody that binds to both gp120 and
gp41
Author(s)
Zhang, M; Yuan, T; Li, J; Borges, AR; Watkins, JD; Guenaga, J;
Yang, Z; Wang, Y; Wilson, R; Li, Y; Polonis, VR; Pincus, SH;
Ruprecht, RM; Dimitrov, DS
Citation PLoS One, 2012, v. 7 n. 9, e44241
Issued Date 2012
URL http://hdl.handle.net/10722/159709
Rights Creative Commons: Attribution 3.0 Hong Kong License
Identification and Characterization of a Broadly Cross-
Reactive HIV-1 Human Monoclonal Antibody That Binds
to Both gp120 and gp41
Mei-Yun Zhang1*, Tingting Yuan1, Jingjing Li1, Andrew Rosa Borges2, Jennifer D. Watkins3,4,
Javier Guenaga5, Zheng Yang1, Yanping Wang6, Richard Wilson5, Yuxing Li5, Victoria R. Polonis7,
Seth H. Pincus8,9, Ruth M. Ruprecht3,4, Dimiter S. Dimitrov6
1AIDS Institute; Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China, 2United States Military HIV Research
Program, Department of Vaccine Research, Henry M. Jackson Foundation, Rockville, Maryland, United States of America, 3Dana-Farber Cancer Institute, Boston,
Massachusetts, United States of America, 4Harvard Medical School, Boston, Massachusetts, United States of America, 5 International AIDS Vaccine Initiative Neutralizing
Antibody Center at TSRI, Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, United States of America, 6CCRNP, Center
for Cancer Research, National Cancer Institute-Frederick, National Institutes of Health, Frederick, Maryland, United States of America, 7United States Military HIV Research
Program, Division of Retrovirology, Walter Reed Army Institute of Research, Rockville, Maryland, United States of America, 8Children’s Hospital, New Orleans, Louisiana,
United States of America, 9 Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States of America
Abstract
Identification of broadly cross-reactive HIV-1-neutralizing antibodies (bnAbs) may assist vaccine immunogen design. Here
we report a novel human monoclonal antibody (mAb), designated m43, which co-targets the gp120 and gp41 subunits of
the HIV-1 envelope glycoprotein (Env). M43 bound to recombinant gp140 s from various primary isolates, to membrane-
associated Envs on transfected cells and HIV-1 infected cells, as well as to recombinant gp120 s and gp41 fusion
intermediate structures containing N-trimer structure, but did not bind to denatured recombinant gp140 s and the CD4
binding site (CD4bs) mutant, gp120 D368R, suggesting that the m43 epitope is conformational and overlaps the CD4bs on
gp120 and the N-trimer structure on gp41. M43 neutralized 34% of the HIV-1 primary isolates from different clades and all
the SHIVs tested in assays based on infection of peripheral blood mononuclear cells (PBMCs) by replication-competent virus,
but was less potent in cell line-based pseudovirus assays. In contrast to CD4, m43 did not induce Env conformational
changes upon binding leading to exposure of the coreceptor binding site, enhanced binding of mAbs 2F5 and 4E10 specific
for the membrane proximal external region (MPER) of gp41 Envs, or increased gp120 shedding. The overall modest
neutralization activity of m43 is likely due to the limited binding of m43 to functional Envs which could be increased by
antibody engineering if needed. M43 may represent a new class of bnAbs targeting conformational epitopes overlapping
structures on both gp120 and gp41. Its novel epitope and possibly new mechanism(s) of neutralization could helpdesign
improved vaccine immunogens and candidate therapeutics.
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Introduction
Development of an effective HIV-1 vaccine will likely require
elicitation of broad and potent neutralizing antibody (nAb)
responses against the envelope glycoprotein (Env). HIV-1 uses
various mechanisms to escape human immune surveillance. Early
HIV-1 infection frequently results in isolate-specific nAbs. A small
percentage of HIV-1-infected individuals gradually develop
broadly cross-reactive HIV-neutralizing antibodies (bnAbs) over
a period of years. Profiling the specificity of bnAbs in the plasma of
such ‘‘elite controllers’’ revealed the presence of high titers of CD4
binding site (CD4bs) Abs or bnAbs specific for other neutralizing
determinants [1,2,3,4]. A great effort has been made to isolate
monoclonal bnAbs (bnmAbs) from such individuals. Four well
studied bnmAbs, the CD4bs mAb b12 [5], the glycan-specific
mAb 2G12 [6,7], and MPER-specific mAbs 2F5 and 4E10 [8,9],
were identified more than a decade ago. Numerous new bnmAbs
that are more potent than these four bnmAbs have been identified
in the past two to three years, including PG9/PG16 [10], HJ16
[11], VRC01-03 [12], and very recently reported PGTs [13],
VRC01-like Abs (VRC-CHs, VRC-PG04) [14], and 8ANCs,
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3BNCs and 12A21 [15], etc. Most of the newly identified potent
bnmAbs recognize the CD4bs or their epitopes overlap with the
CD4bs. Others recognize variable loops and glycans of gp120
subunit. Co-crystallization of some of the bnmAbs with gp120 core
protein or Env-derived peptides has revealed several conserved
neutralizing epitopes [6,15,16,17,18,19,20,21]. Both b12 and
VRC01 used their heavy chain complementarity-determining
region 2 (HCDR2) to mimic CD4 binding to gp120 with some
differences. A critical b12 residue mimics the interaction of the
CD4 phenylalanine (Phe43CD4), while a critical VRC01 residue
mimics the interaction of the CD4 arginine (Arg59CD4) with gp120
[16,17]. Two genetically related bnmAbs, PG 9/16, have one of
the longest HCDR3 (28 amino acids, AA) observed for human
antibodies and preferentially recognize the oligomeric conforma-
tion of the Env. PG9 binds to a site of vulnerability comprising of
two conserved glycans and one of the four b-strands formed by the
V1/V2 loops with the long protruding H3 loop penetrating the
glycan shield [19]. Similarly, PGT 127 and 128 bind to a high
mannose site on gp120, and the antibody penetrates the glycan
shield and recognizes two conserved glycans and a short b-strand
segment of the V3 loop [21]. PG16 and the recently reported
CH01-CH04 and PGT145 may share this binding mode of glycan
penetration by extended anionic loops. 2F5 and 4E10 recognize
linear epitopes on the MPER of gp41 that is thought to play a key
role in the fusion process [8,9]. 2G12 is a unique bnmAb that has a
domain-swapping feature and recognizes a cluster of oligoman-
nose residues on gp120 [6,7]. These neutralizing epitopes may be
used for vaccine immunogen design although such effort based on
the epitopes of b12, 2F5, 4E10 and 2G12 has not been successful.
Identification of novel bnmAbs may reveal new neutralizing
determinants and facilitate immunogen design.
Among the above mentioned bnmAbs, b12 was the only mAb
isolated by antibody phage display [5]. PG9/16, VRC01-03 and
PG9/16-like Abs were isolated by single memory B-cell-sorting in
combination with high-throughput screening for bnAb-secreting B
cells [12,22]. 2F5, 4E10 and 2G12 were isolated by conventional
Epstein-Barr Virus (EBV)-mediated immortalization of antibody-
secreting B cells, while HJ16 was isolated by using an improved
EBV-mediated memory B cell immortalization method in
combination with high-throughput parallel screening with a panel
of recombinant Env-based antigens. We developed the compet-
itive antigen panning (CAP) methodology for isolation of gp41-
specific mAbs that bind to Env. After panning a phage-displayed
immune antibody Fab library by CAP and screening the panned
libraries for gp41-specific mAbs, we found one mAb, designated
m43, which bound to both gp120 and gp41, as well as to
recombinant gp140s. We extensively characterized m43 for
binding and neutralizing activities and possible mechanism of
neutralization. M43 exhibited unique features in binding to Env
trimers and may represent a new class of bnAbs.
Materials and Methods
Cells, viruses, plasmids, gp120, gp140, gp41Fc fusion
protein, peptides and antibodies
This study was approved by the ethics committee of Walter
Reed Army Institute of Research (WRAIR) IRB
(FWA#00000015/IRB00000794). Initial WRAIR IRB approval
was on 5 March 2008. Written consent was received by all
participants of this study. 293T cells were purchased from ATCC.
Free-style 293 cells were purchased from Invitrogen. TZM-bl cell
line and HIV-1 isolates were obtained from the NIH AIDS
Research and Reference Reagent Program (ARRRP). JC-53 and
JC-10 cells were kindly provided by Dr. David Kabat [23]. H9/
NL4-3 is a derivative of the CD4+ human lymphoma cell line H9
that has been infected with the NL4-3 isolate of HIV-1. These cells
maintain complete infection and, through repeated passages in
tissue culture, produce infectious virus [24]. C8166.R5 cells are
CD4+ lymphoma cells that have been transfected to express
CCR5 [25]. Recombinant gp140s from primary isolates for
ELISA along with recombinant gp140/12089.6, gp140/120CM243
and gp140/120R2 for panning and screening were generously
provided by Dr. Christopher C. Broder (USUHS, Bethesda,
Maryland). The cleavage-competent JRFL gp160 plasmid was
kindly provided by Dr. Joseph Sodroski. Wild-type gp41Fc fusion
protein (gp4189.6 fused to human Fc) was produced in our
laboratory by transient transfection of free-style 293 cells using
293fectin as transfection reagent (Invitrogen). The human mAbs
2F5 and 4E10 were kindly provided by Dr. Herman Katinger.
The 6-helix bundle (6HB)-specific mouse mAb NC-1 and 5-helix
bundle (5HB) were kindly provided by Dr. Shibo Jiang (Fudan
University, China). N36 and C34 were provided by Dr. Robert
Blumenthal (NCI, NIH). Peptides DP178 and #7010 were kindly
provided by Dr. Lai-Xi Wang (University of Maryland). MAbs
m14, m18, m43, m44, m46, m48, b12, VRC01, and Z13 were
produced in our laboratories. Fm-6 was provided by Dr. Wayne
Marasco (Dana-Farber Cancer Institute). CD4-IgG2 was a kind
gift of William Olson. Human mAbs 2.2b, A32, E51, and 17b
were provided by Dr. James Robinson. 7B2 is a human mAb
directed against the gp41/gp120 interaction region [26], as is 2.2b;
CD4-IgG2 is a CD4/Ab chimera in which H and L chain V
domains are replaced with CD4 domains 1 and 2 [27]; E51, 17b,
and A32 are human mAbs directed against conserved epitopes of
gp120. 924 is a murine mAb directed against the V3-loop of the
IIIB isolate of HIV [28]. The anti-V3 mAb 39F was obtained from
ARRRP. The plasmid encoding Z13 was provided by Drs. M.
Zwick and D. Burton (The Scripps Research Institute). Anti-p24
mAb (183-12H-5C) and HIV immunoglobulin (HIVIG) were
obtained from the NIH ARRRP. The following antibodies were
purchased: Affinity Purified Sheep Anti-HIV-1-gp120 polyAb
D7324 (AALTO, Dublin, Ireland), HRP-conjugated monoclonal
mouse anti-M13 antibody (Pharmacia, Uppsala, Sweden), HRP-
conjugated polyclonal anti-human IgG, F(ab9)2 antibodies (Jackson
ImmunoResearch, Westgrove, PA), HRP-conjugated streptavidin
(Zymed Laboratories Inc., San Francisco, CA), Phycoerythrin
(PE)-conjugated polyclonal anti-human IgG, F(ab9)2 antibodies
and PE-conjugated streptavidin (Jackson ImmunoResearch, West-
grove, PA).
Competitive Antigen Panning (CAP) and screening
The phage library was constructed using pComb3H phagemid
vector and 30 ml of bone marrow obtained from three long-term
nonprogressors (A, H and K) [29] whose sera exhibited the
broadest (against six primary isolates [30]) and most potent
(against JR-FL at 1:40 dilution) HIV-1 neutralization amongst the
37 HIV-1-infected individuals [31]. CAP was performed as
described previously [32]. Briefly, the phage library
(561012 cfu/ml) was preabsorbed on streptavidin-M280-Dyna-
beads in PBS for 1 h at room temperature (RT) and incubated
with 50 nM biotinylated HIV-1 CM243 (clade E) Env
gp140CM243 and 250 nM non-biotinylated gp120CM243 (5-fold
more on molar level than biotinylated gp140CM243) for 2 h at RT
with gentle agitation. Phage particles binding to biotinylated Env
were separated from the phage library using streptavidin-M280-
Dynabeads and a magnetic separator (Dynal). After washing 20
times with 1 ml of PBS containing 0.1% Tween-20 and another
20 times with 1 ml of PBS, bound phage particles were eluted
from the beads using 100 mM Triethanolamine followed by
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neutralization with 1 M, pH7.5 Tris-HCl. For the 2nd round of
panning, 10 nM (2 nM for the 3rd round) of biotinylated
gp140CM243 was used as antigen and a 5-fold excess of non-
biotinylated gp120CM243 for competition depletion. After 3
rd
round of panning against 2 nM biotinylated gp140CM243 in the
presence of 10 nM non-biotinylated gp120CM243, 96 individual
clones were screened for binding to gp140CM243, gp120CM243, and
gp41Fc fusion protein by phage ELISA.
Binding assays with recombinant Env glycoproteins or
peptides
ELISAs of soluble Fab m43 to recombinant HIV-1 gp140s,
gp120 and gp41Fc fusion protein were performed by directly
coating gp140s on 96-well plates followed by addition of three-fold
serially diluted soluble Fab m43. Bound Fab m43 was detected
using HRP-conjugated anti-human IgG, F(ab9)2 (1:5,000) and
ABTS substrate. In cases using denatured gp140s, purified gp140s
were diluted in 1% sodium dodecyl sulfate-50 mM DTT to
10 mg/ml and boiled for 5 min, then diluted 1:10 in PBS and
coated on 96-well plates. Competition ELISA was performed by
directly coating recombinant gp14089.6 followed by addition of
serially diluted competitors, either gp41-derived peptides or fusion
intermediate structures or HIV-1 mAbs, and a fixed concentration
of non-biotinylated HIV-1 mAbs or biotinylated IgG1 m43 that
leads to 50–70% maximum binding. Bound Fabs (m43 and m44)
and IgG1s (2F5 and 4E10) were detected using HRP conjugated to
anti-human IgG, F(ab9)2 (1:5,000) and ABTS substrate. Bound
mouse mAbs NC-1 was detected using HRP-conjugated anti-
mouse (H+L) (1:5,000) and ABTS substrate. Bound biotinylated
IgG1 m43 was detected by HRP-avidin (1:10,000) and ABTS
substrate. Binding to gp120 loop deletion mutants and site mutants
were carried out by coating sheep anti-HIV-1 poly Ab D7324 (at
5 mg/ml) to capture WT gp120 or mutants in culture supernatant
followed by addition of serially diluted mAbs in duplicates.
Western blots with gp41 intermediate structures were done as
previously described [33,34,35,36]. NCCG-gp41 (13), N35CCG-
N13, and N34CCG, as well as single chain protein of five helix
bundle (5HB) were recombinant polypeptides. N36/C34 -formed
six helix bundle (6HB) was prepared by equally (on molar ratio)
mixing synthesized linear peptide N36 and C34 followed by
incubation at RT for 30 min.
Flow cytometry
Using PEI as transfection reagent, 293T cells were cotransfected
with cleavage-competent Env-expressing plasmid or cleavage-
incompetent Env-expressing plasmid, JRFL or Yu2 gp160dCT/
pSVIII, and HIV-1 Tat-expressing plasmid pCTAT. Six hrs
posttransfection, the medium was changed to complete medium
(DMEM with 10% FBS). 48 hrs posttransfection, cells were
detached using trypsin-free cell dissociate buffer and washed with
PBS. 26105 cells were aliquoted to each microcentrifuge tube for
each ligand at a given concentration. The tubes containing the
cells were subjected to centrifugation at 3506 g for 5 min at RT.
The cell pellets were resuspended in 100 ml Fluorescence-activated
cell sorting (FACS) buffer containing the ligands and incubated at
RT for 60 min. Following another two times washing, the cells
were incubated with appropriate 2nd antibody in100 ml FACS
buffer at RT for 60 min. The stained cells were analyzed by FACS
on a Beckman Coulter Calibur Instrument. Indirect immunoflu-
orescence with persistently infected H9/NL4-3 cells or C8166.R5
cells five days after acute infection with the R5 tropic HIV isolates
Ba-L or 208/K8was performed by incubating cells for 1 hr with
primary Abs diluted to 10 mg/ml in PBS containing 1% BSA and
0.01% sodium azide (PBA). Where indicated, sCD4 (a gift of
Upjohn) was added at 500 ng/ml. After the primary incubation,
cells were washed twice then incubated with FITC or Alexa 488-
conjugated anti-mouse or anti-human Ig (3 mg/ml) (Invitrogen).
Following another set of washes, the cells were fixed with 2%
paraformaldehyde. 10,000 cells per run were analyzed on an
LSRII flow cytometer. Ab interactions were studied by incubating
cells with unconjugated Abs (10 mg/ml) in PBA for 1 hr, then
adding directly-labeled Ab (3 mg/ml) to the cells. After 4 hrs, the
cells were washed, fixed in 2% paraformaldehyde and studied by
flow cytometry.
HIV-1/SHIV neutralization assays
Three neutralization assays based on infection of PBMCs were
carried out in this study. The PBMC-p24 assay was carried out
using the protocol previously described [37]. PBMCs isolated from
the blood of healthy donors were plated in 75-cm2 plastic flasks
and incubated at 37uC for 2 hrs. The nonadherent cells were
collected and resuspended at 56106 in 10 ml of RPMI 1640
medium containing 10% FBS, 5 mg/ml of phytohemagglutinin
(PHA), and 100 U/ml of IL-2, followed by incubation at 37uC for
3 days. The PHA-stimulated cells were infected with the
corresponding primary HIV-1 isolates at a multiplicity of infection
(MOI) of 0.01 in the absence or presence of an antibody at graded
concentrations. Culture media were changed every 3 days. The
supernatants were collected seven days post infection and tested
for p24 antigen by ELISA. The percent inhibition of p24
production was calculated by using the software Calcusyn. The
PBMC-RT assay was carried out as follows: 100 ml of antibodies
diluted in complete RPMI with IL-2 were incubated with 50 ml of
virus containing 100 TCID50 for 30 min at 37uC and added to
50 ml of PHA-activated PBMCs (16106) in complete RPMI 1640
with IL-2. The calculated neutralization activities refer to the
antibody concentration present during this incubation step.
Triplicate samples were taken on day 7 for the RT assay and
percentage neutralization was calculated by dividing the RT
activity of the tested samples by the RT activity of mock culture
without antibody; AZT was used as a positive control with 100%
inhibition at a concentration equal to 0.1 mM, where the measured
cell toxicity was undetectable (IC50 = 0.002 mM, TCID50.1 mM).
The SHIV neutralization assays were performed in human
PBMCs followed by SIV p27 readout. The mAbs were tested
against SHIV-1157ipd3N4 [38], SHIV-1157ipEL-p [39], SHIV-
2873Nip [40] and SHIVSF162P4 [41], as previously described [38],
except that polymyxin B (15 mg/ml) was added to block potentially
present endotoxin [42]. The assay was repeated twice.
Three cell lines, TZM-bl, JC-10, and JC-53, were used in cell
line-based pseudovirus assays. The TZM-bl cell line-based assay
was carried out in triplicate by using an HIV-1 Env pseudotyping
system and TZM-bl target cells containing a Tat-inducible
luciferase reporter and expressing CD4, CCR5, and CXCR4.
The degree of virus neutralization by antibody was achieved by
measuring luciferase activity as described previously (assay #2 in
[43]). Percentage of virus neutralized was calculated as the number
of isolates neutralized by the mAb over the total number of isolates
tested. JC-10 and JC-53 cell line-based assay is very similar to
TZM-bl cell line-based assay except the target cells are changed
from TZM-bl cells to JC-10 or JC-53 cells that express different
level of coreceptor CCR5 [23,44]. VSV-G pseudotype controls
were included in the assays. IgG1 m43 did not neutralize VSV-G
pseudotype virus.
HIV-1 Env gp120 shedding
HIV-1 Env shedding assay was performed as previously
described [45]. About 8 million 293T cells were seeded and
Monoclonal Antibody Cotargeting gp120 and gp41
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transfected with 40 mg of plasmid JRFLgp160dCT/pSVIII along
with 2 mg of Tat-expressing plasmid pCTAT, with Fugene6
(Roche) as transfection reagent per the manufacturer’s instruc-
tions. 48 hrs post transfection, the cells were dislodged from the
cell culture flask by incubating with PBS/5 mM EDTA and gently
rocking at RT for 5 min. Cells were then washed with PBS and
resuspended at density of to 16107 cells/ml in PBS. 200 ul of the
cell suspension (about 2 million cells) were aliquoted into micro-
centrifuge tubes for the shedding assay for each antibody/ligand.
The cells were pelleted by centrifugation at 3356 g at RT for
5 min. 160 ml of the supernatant was removed and 20 ml of the
ligand stock solution were added to the cell pellets to achieve a
final concentration of 50 mg/ml. The cells and ligand were mixed
well and incubated at 37uC for 1 hr with gentle mixing every
20 min. The cells were then pelleted by centrifugation, and the
supernatants were transferred to fresh tubes. 30 ml of each
supernatant was loaded onto SDS-PAGE gels and run for
1.5 hrs at 200 V. The proteins from the supernatant were
transferred from the gel to nitrocellulose membranes for Western
blotting analysis. To identify shed gp120, anti-gp120 human mAb
39F (V3-specific) was used as a primary antibody (1 mg/ml) in
PBS/0.1% Tween-20, and HRP-conjugated anti-human poly-
clonal antibodies as secondary antibody (1:10,000), followed by
development with Immobilon Western Chemiluminescent HRP
substrate (Millipore).
Results
Isolation of a broadly cross-reactive human mAb co-
targeting gp120 and gp41
Panning of a phage-displayed antibody library against recom-
binant gp140 often results in enrichment of gp120-specific
antibodies. To identify antibodies specific for gp41 in the context
of the Env, we developed the CAP methodology [32,46] and
isolated a panel of broadly cross-reactive gp41-specific mAbs,
including m44 [33], m46 [47], and m48 [32]. Using biotinylated
recombinant gp140CM243, gp14089.6 and gp140R2 in the presence
of corresponding 5-fold more non-biotinylated recombinant
gp120CM243, gp12089.6 and gp120R2, we carried out three rounds
of CAP against each antigen. During screening using the
gp140CM243-panned library for gp41-specific monoclonal phage,
we found one clone, designated m43, which strongly bound all
antigens used in monoclonal phage ELISA, including recombinant
gp140CM243, gp120CM243, and 89.6 gp41Fc fusion protein. Fab
m43 was not enriched in the panned libraries against gp140CM243
and was not found in 192 individual clones from the panned
libraries against gp14089.6 and gp140R2, which is most likely due to
Figure 1. m43 sequence and extent of affinity maturation. The sequence of m43 is shown along with nearest VH- and VK-genomic precursors
for heavy and light chain V-segments, respectively. Affinity maturation changes in V-segments are indicated in green.
doi:10.1371/journal.pone.0044241.g001
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Figure 2. Binding of m43 and control mAbs to recombinant Envs by ELISA (A–E) and to gp41 intermediate structures by Western
blot (F). A: Binding of Fab m43 to recombinant gp140s, gp120s and gp41Fc fusion protein. B: Binding of Fabs m43 and Z13, and IgG1 2F5 to non-
denatured (solid symbols) and denatured gp14089.6 (empty symbols). C: Binding of Fabs m43, m44 and Z13, and mouse mAb NC-1 to recombinant
gp14089.6 in the absence (solid symbols) or presence (empty symbols) of sCD4 (2 mg/ml). D: Competition of CD4bs mAbs b12, m18 and VRC01, CD4i
mAbs m16 and m9Fc fusion protein, and gp41-specific mAbs m44, m46, 2F5 and 4E10 with biotinylated IgG1 m43 for binding to coated gp14089.6. E:
EC50s of IgG1 m43, CD4bs mAbs b12 and VRC01, CD4i mAb 17b, and V3 loop-specific mAb 39F with gp120JRFL wild-type (WT) and V1, V2, V3 loop
deletion mutants, and gp120yu2 WT and its site mutants in CD4bs (D368R), CD4i (I420R), loop D (N279E) and V5 loop (G459E). nd: not done. F: Binding
of Fabs m43 and m44 to non-reduced N35CCG-gp41 (lane 1), N35CCG-N13 (lane 2), N34CCG (lane 3), gp41 core (lane 4), and 5HB (25.4 kDa) (lane 5) by
Western blot.
doi:10.1371/journal.pone.0044241.g002
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the excessive amount of respective recombinant gp120s used for
competition depletion. Sequence analysis showed that m43 had
extensive somatic maturation in both heavy and light chain
variable regions (VH and VL) (Fig. 1).
Characterization of the m43 epitope
We expressed Fab m43 and characterized it for binding activity.
Soluble Fab m43 bound to a panel of recombinant gp140s derived
from different clades with affinities ranging from 1–30 nM except
the recombinant gp140 derived from clade A isolate, UG037.8
(Table 1), suggesting that m43 epitope is conserved among gp140s.
Fab m43 also bound to various recombinant gp120s, as well as to
89.6 gp41Fc fusion protein (Fig. 2A). Fab m43 bound to
recombinant gp120BaL fused to the first two domains of CD4
(BaLgp120-d1d2) with affinity higher than that for BaL gp120
alone (Fig. 2A). But Fab m43 did not bind to denatured
recombinant gp14089.6 (Fig. 2B), indicating a conformational
nature of the m43 epitope. Soluble CD4 (sCD4) weakly inhibited
Fab m43 binding to recombinant gp14089.6, while it did not affect
the binding of gp41-specific human mAbs m44, Z13, and mouse
mAb NC-1 to recombinant gp14089.6 (Fig. 2C). In an attempt to
localize the m43 epitope, we performed a competition ELISA of
Fab m43 with N36/C34-formed six helix bundle (6HB), single-
chain protein of five helix bundle (5HB), gp41-derived peptides
N36, C34, and 2F5 epitope containing (underlined) peptides DP178
(YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNF), and
#7010 (NEQELLELDKWASLWNWFD). None of these compet-
itors inhibited Fab m43 binding to coated recombinant gp14089.6
(data not shown). We then performed another competition ELISA
of IgG1 m43 with a panel of HIV-1 mAbs for binding to coated
recombinant gp14089.6 (Fig. 2D). IgG1 m43 competed strongly with
CD4bs mAbs b12 and m18, and modestly with CD4bs mAb
VRC01 and CD4 induced (CD4i) mAbs m16 and m9Fc fusion
protein. IgG1 m43 did not compete with gp41-specific mAbs m44,
m46, and MPER-specific mAbs 2F5 and 4E10, which is consistent
with the result obtained from the competition ELISA of Fab m43
with peptides DP178 and#7010. We further measured the binding
of IgG1 m43 to gp120JRFL V1, V2, V3 loop deletion mutants, and to
four gp120yu2 site mutants with knock-out mutations in the CD4
binding site (D368R), the coreceptor binding site (I420R), loop D
(N279E), and V5 loop (G459E) in comparison with CD4bs mAbs
b12 and VRC01, CD4i mAb 17b, and V3 loop-specific mAb 39F
(Fig. 2E). Results showed that deletion of V1, V2 or V3 loop did not
affect m43 binding to gp120. Site mutations in the coreceptor
binding site, loop D or V5 also did not affect m43 binding to gp120,
but site mutation in CD4bs (D368R) abolish m43 binding to
gp120YU2. All these results indicate that m43 epitope may involve
the CD4bs on gp120. The competition between IgG1 m43 and
CD4i mAbs may be due to steric restrictions. To localize m43
epitope on gp41, we measured the binding of Fab m43 to fusion
intermediate structures, including N36/C34-formed 6HB, single-
chain protein of 5HB and the N-trimer-containing polypeptides
Nccg-gp41 [34], N35ccg-N13 [35], and N34ccg [35] by Western blot
in comparison with Fab m44 [33,36] (Fig. 2F). Fab m43 bound to
N35ccg-N13 and N34ccg containing N-trimer structure (lane 2 and
3), suggesting that the N-trimer structure of gp41may be involved in
m43 binding. Fab m43 did not bind to the 5HB (lane 5) and the
6HB (lane 4), nor to the Nccg-gp41 (lane 1) that comprises 6HB and
N-helix. As we reported previously, Fab m44 bound to 5HB and
6HB, as well as Nccg-gp41 on Western blot [33]. Taken together,
these results suggest that m43 binds to a conserved and
conformational epitope that may involve the CD4 binding site on
gp120 and the N-trimer structure on gp41.
Existence of the m43 epitope on functional Env trimers
We tested IgG1 m43 for binding to functional Env trimers by
flow cytometry in comparison with IgG1s b12, VRC01, 2F5 and
4E10 (Fig. 3A). M43 bound to cleavage-competent JRFL gp160
on 293T cells, and its binding was slightly enhanced by sCD4. The
binding of 2F5 and 4E10 to cleavage-competent JRFL gp160 was
lower than that of m43, and their binding was also slightly
enhanced by sCD4 (Fig. 3A). Both b12 and VRC01 showed strong
binding to cleavage-competent JRFL gp160. As expected, sCD4
inhibited both b12 and VRC01 binding (Fig. 3A). We compared
IgG1 m43 binding to cleavage-competent JRFL gp160 with its
binding to cleavage-competent Yu2 gp160 and cleavage-incom-
petent JRFL and Yu2 gp160s by flow cytometry in comparison
with 2F5 and 4E10 (Table 2). Both IgG1 m43 and 4E10 showed
significantly higher binding to cleavage-competent Yu2 gp160
than to cleavage-competent JRFL gp160, while 2F5 binding to
both cleavage-competent JRFL and Yu2 gp160s were almost the
same. All three mAbs showed increased binding to cleavage-
competent JRFL gp160 in the presence of sCD4. sCD4 enhanced
m43 the most (about 2-fold increase) and, to less extent, 2F5 and
4E10 in binding to cleavage-competent JRFL gp160. All three
mAbs showed higher binding to cleavage-incompetent JRFL and
Yu2 gp160s than to the cleavage-competent counterparts, but the
changes with m43 were more prominent (about 5-fold increases)
than those with 2F5 and 4E10 (about 2-fold increases). sCD4 also
slightly enhanced 2F5 and 4E10 binding to cleavage-competent
Yu2 gp160s, while sCD4 weakly inhibited m43 binding to
cleavage-competent Yu2 gp160 (Table 2). These results suggest
that m43 bound better than 2F5 and 4E10 to functional Env
trimers, and the binding of m43 and 2F5 was more conformation-
dependent than 4E10.
We then measured IgG1 m43 binding to HIV-1-infected cells,
including C8166 cells acutely infected with the HIV-1 isolate BaL
or K8 (R5-tropic), and H9 cells chronically infected with HIV-1
isolate NL4-3 (X4-tropic), and the effect of sCD4 on m43 binding
to H9/NL4-3 cells in comparison with gp41-specific mAbs m44,
7B2 and 2F5 (Fig. 3B–C). M43 bound to the viral spikes of all
three isolates on target cells although m43 binding to acutely
infected C8166 cells was weaker than the binding of other mAbs
(Fig. 3B). Unlike m44 and 7B2, whose binding to H9/NL4-3 cells
Table 1. Binding of Fab m43 to recombinant gp140s from
primary isolates.
Isolate Clade EC50, nM
Fab m43
UG037.8 A 500 6 291.5
tethered 89.6 B 3 6 0.8
R2 B 3.5 6 0.7
MW965.26 C 12.3 6 8.3
GXC-44 C 1.5 6 0.2
CRII92UG024.2 D 5.4 6 0.2
GXE-14 E 1.9 6 0.2
93BR019.10 FB 35.9 6 14.3
92UG975.10 G 1.7 6 0.4
Recombinant gp140s from primary isolates were directly coated on Maxisorp
plates. Bound Fab m43 was detected by using HRP conjugates to anti-human
IgG, F(ab9)2 as secondary antibody and ABTS as substrate. EC50 is the
concentration at which antibody has half-maximum binding.
doi:10.1371/journal.pone.0044241.t001
Monoclonal Antibody Cotargeting gp120 and gp41
PLOS ONE | www.plosone.org 6 September 2012 | Volume 7 | Issue 9 | e44241
was enhanced by sCD4, the binding of m43 was inhibited by
sCD4 (Fig. 3C). We further characterized m43 for binding to H9/
NL4-3 cells by competition flow cytometry with other HIV-1
mAbs (Fig. 3D). Unlike other gp120 and gp41 Abs, m43 inhibited
the binding of b12, VRC01 and CD4-IgG2. M43 has little effect
on the binding of other Abs to infected cells. These results suggest
that m43 epitope is exposed in functional Env trimers and overlaps
with the CD4bs.
Neutralization activity of m43 against primary HIV-1
isolates and SHIVs
To characterize m43 for neutralization activity, we tested IgG1
m43 with primary HIV-1 isolates in cell line-based pseudovirus
assays and in neutralization assays based on infection of PBMCs
and measurement of p24 (PBMC-p24), or p27 (PBMC-p27), or
RT (PBMC-RT) produced by infected cells. We first tested IgG1
m43 with a panel of 30 primary isolates from clade A, B, C, D and
cross-clade AE and AG in PBMC-p24 assay and in TZM-bl
pseudovirus assay in comparison with the CD4bs mAbs m14,
m18, b12, CD4i mAb scFv m9, and gp41-specific mAbs m48, 2F5
and 4E10. HIV-1 infected patient sera pool 21.2 was included as a
control in the assay (Table 3). Consistent with the observation
reported previously, 2F5 and 4E10 were much more potent in
TZM-bl assay than in PBMC assay. In contrast, IgG1 m43
neutralized the tier 2 or tier 3 viruses from each clade (A, B, C, D,
AE, AG) tested in PBMC-p24 assay, but only two tier 1 virus from
Figure 3. Binding of IgG1 m43 and other mAbs to functional Env trimers by flow cytometry. A. Binding of IgG1s m43, b12, VRC01, 2F5 and
4E10 to cleavage-competent gp160JRFL on 293T cells. B. Binding of Abs to C8166.R5 cells five days after acute infection with the R5-tropic HIV isolates
BaL or 208/K8. C. Binding of mAbs (3 mg/ml) to persistently infected H9/NL4-3 cells in the presence or absence of sCD4 (500 ng/ml). D. The ability of
seven different unconjugated mAbs to alter the binding of eleven Alexa 488-labeled Abs to H9/NL4-3 cells. The results are displayed as the mean and
SEM fluorescent intensity, with each graph representing one labeled Ab. The vertical line on each graph indicates the binding of the labeled Ab in the
absence of unlabeled Ab. Fluorescent intensity values for unlabeled cells were 26063, and for cells incubated with an Alexa 488-labeled isotype
control 29862.
doi:10.1371/journal.pone.0044241.g003
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clade B and one tier 2 and one tier 3 viruses from clade D in
TZM-bl assay. CD4i scFv m9 also showed increased potency in
PBMC-p24 assays than in TZM-bl assays, which is consistent with
the observation we reported previously [44]. TZM-bl cells have
much higher coreceptor (CCR5 and CXCR4) surface density than
PBMCs [44]. To investigate if m43 neutralization activity depends
on the coreceptor density on target cells, we tested IgG1 m43
against a panel of clade B isolates in a pseudovirus assay using JC-
10 (low CCR5) and JC-53 (high CCR5) as indicator cells in
comparison with potent neutralizer VRC01 (Table 4). M43
exhibited higher inhibitory activity against JRFL (R5), JRCSF (R5)
and 89.6 (R5X4) in JC-10 cells than in JC-53 cells, but lower
inhibitory activity against BaL (R5) in JC-10 cells than in JC-53
cells and no difference in inhibiting entry of HxB2 (X4) into both
cell lines, suggesting that the coreceptor density alone may not
determine the neutralization activity of m43 in cell line-based
assays.
We then tested IgG1 m43 with another panel of primary isolates
from different clades by PBMC-RT assay in comparison with
other three gp41-specific IgG1s m44, m48 and 4E10 (Table 5).
IgG1 m43 neutralized all HIV-1 isolates tested in PBMC-RT assay
except clade O isolate (BCF03). M43 exhibited neutralization
activity that is comparable to or higher than that of m44, m48 and
4E10 against this panel of isolates by PBMC-RT assay (Table 5).
We further tested IgG1 m43 with three clade C SHIV strains, the
tier 2 SHIV-1157ipd3N4 [38] and SHIV-2873Nip [40] and the
tier 1 SHIV-1157ipEL-p [39], and one clade B SHIV strain, the
tier 1 SHIVSF162P4 [41], in a PBMC-p27 assay [38]. Because
VRC01 is extremely potent (IC50 less than 0.16 mg/ml) against the
four SHIVs, it was used as positive control, while Fm-6 served as
negative isotype control. IgG1 m43 potently neutralized all SHIVs
tested with IC50 values ranging from 0.7 to 4.9 mg/ml (Fig. 4).
These results indicate that m43 targets a conserved epitope among
the four SHIVs.
Markedly different effects of IgG1 m43 and CD4 on
functional Env trimer epitope exposure and on gp120
shedding
To elucidate the mechanism of neutralization by m43, we
investigated the effect of m43 on exposure of the coreceptor
binding site and the MPER in the context of a functional Env
trimer (Fig. 5). Unlike CD4, binding of m43 to cleavage-
competent JRFL gp160 on 293T cells did not enhance the
binding of CD4i mAb 17b and MPER-specific mAbs 2F5 and
4E10 to gp160. Instead, m43 inhibited 17b binding to the
functional Env trimer. IgG1 m43 also slightly inhibited the
binding of 2F5 to the functional Env trimer. 4E10 weakly bound to
cleavage-competent JRFL gp160 and the effect of m43 on 4E10
binding was not obvious (Fig. 5). We further tested gp120 shedding
upon m43 binding to cleavage-competent JRFL gp160 on 293T
cells. Unlike CD4, m43 does not induce gp120 shedding upon
binding, which is similar to the binding of VRC01 and b12 (Fig. 6).
These observations suggest that binding of m43 to functional Env
trimer may lock the Env in a non-fusogenic conformation, leading
to inhibition of virus entry.
Different binding patterns of IgG1s m43, VRC01 and b12
to cleavage-competent and cleavage-incompetent
gp160s
When we measured the binding of IgG1 m43 to cleavage-
competent JRFL gp160 in comparison with the binding of b12
and VRC01 by flow cytometry, we noticed that increased
concentration of b12 and VRC01 led to dramatic increase in
binding, while the binding of m43 was independent of m43
concentration. We then tested various concentrations of IgG1s
m43, VRC01 and b12 for binding to cleavage-competent and
cleavage-incompetent JRFL and Yu2 gp160s by flow cytometry
(Fig. 7). It turned out that increased concentrations of VRC01 led
to dramatically increased binding (2-4-fold increases in mean
fluorescence intensity, MFI) of VRC01 to both cleavage-compe-
tent and cleavage-incompetent JRFL and Yu2 gp160s (Fig. 7).
Increased concentrations of m43 and b12 also led to increased
binding of m43 and b12 to cleavage-competent Yu2 gp160 (about
20% increases in MFI), but the increases with m43 and b12 were
not as significant as that with VRC01. The binding pattern of b12
to cleavage-competent Yu2 gp160 was similar to that of m43,
although b12 showed higher binding than m43 (Fig. 7). Both m43
and b12 showed high binding to cleavage-competent Yu2 gp160
and cleavage-incompetent JRFL and Yu2 gp160s, but their
binding patterns were different. The binding of b12 to cleavage-
competent Yu2 gp160 increased as the concentration of b12
increased, while the binding of b12 to cleavage-incompetent JRFL
and Yu2 gp160s appeared to be independent of b12 concentra-
tion. The binding of m43 to cleavage-competent Yu2 gp160
increased as the concentration of m43 increased, while the binding
of m43 to cleavage-incompetent JRFL and Yu2 gp160s increased
as the concentration of m43 increased from 2 mg/ml to 10 mg/ml,
but did not change as the concentration of m43 increased further
(from 10 mg/ml to 50 mg/ml) (Fig. 7). The mechanisms for the
different binding patterns of different mAbs remain to be
elucidated.
Discussion
Since the discovery of HIV-1 nearly three decades ago, an
effective HIV-1 vaccine that can elicit bnAbs has yet to be
developed. Identification of novel neutralizing determinants may
help achieve this goal. We identified and extensively characterized
a novel cross-reactive human mAb m43 that recognizes a new
conserved neutralizing epitope shared by gp120 and gp41. Since
the crystal structure of Env trimer is not available, we are not sure
if m43 epitope is jointly formed by the CD4bs on gp120 and the
N-trimer structure on gp41, or if m43 has dual specificity for one
epitope on gp120 and another on gp41, which is very rare.
Nevertheless, the m43 epitope is present on functional Env trimer
and binding of m43 to viral Env prevents virus entry into target
Table 2. Binding of IgG1s m43, 2F5 and 4E10 to cleavage-
competent and cleavage-incompetent JRFL and Yu2 gp160s
on 293T cells in the absence and presence of 10 mg/ml sCD4
by flow cytometry.
mAbs MFI
JRFL(+) JRFL(2) Yu2(+) Yu2(2)
2nd Ab only 6.0 4.8 7.2 6.3
m43 46.8 183.0 191.0 1026.6
m43+sCD4 88.0 196.6 181.8 917.8
2F5 20.8 82.2 26.3 62.9
2F5+sCD4 26.5 77.3 31.7 48.9
4E10 19.3 25.1 76.9 116.4
4E10+sCD4 21.2 23.7 84.5 97.0
Each mAb was tested at 10 mg/ml concentration. (+): cleavage-competent
gp160s, (2): cleavage-incompetent gp160s.
doi:10.1371/journal.pone.0044241.t002
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cells. Although m43 exhibited modest neutralization activity
compared to potent bnmAb VRC01, it neutralized tier 1, 2 and
3 viruses from different clades and four SHIVs tested. M43
showed higher binding to cleavage-incompetent JRFL and Yu2
gp160s than to cleavage-competent JRFL and Yu2 gp160s, which
may be attributed to the fact that uncleaved recombinant gp140s
were used as antigens during the panning and screening for
isolation of m43. Antibody engineering is in progress to improve
m43 binding to cleavage-competent JRFL gp160. Improved dual
binding to gp120 and gp41 may lead to broader and more potent
neutralization activity of the antibody as exemplified by an
engineered bispecific anti-HIV-1 antibody that can bind bivalently
by virtue of one single chain antibody fragment (scFv) arm that
binds to gp120 and a second arm to the gp41 subunit of gp160
[48]. Heterotypic bivalent binding enhanced neutralization
compared with the parental antibodies. M43 may represent a
new class of bnAbs and its epitope may be used for development of
HIV-1 vaccine immunogens.
Characterization of the m43 epitope revealed that m43 bound
to a conformational epitope that overlaps with the CD4bs on
gp120 and the N-trimer structure on gp41. We tried to localize
m43 epitope by panning a yeast-displayed Env fragment library
against Fab m43, but no enrichment was observed (data not
shown). CD4bs mAbs strongly competed with m43 for binding to
recombinant gp140s and membrane-associated functional Env
trimers (Fig. 2D and 3D), suggesting that m43 epitope overlaps
with the CD4bs. The coreceptor binding site may not be involved
in m43 binding as evidenced by lack of correlation between
coreceptor density on target cells and m43 neutralization activity.
The modest competition of CD4i mAbs with m43 for binding to
Table 3. Percentage neutralization of IgG1s m43, m48, m14, m18, b12, 2F5 and 4E10 at 30 mg/ml against 30 HIV-1 primary isolates
from different clades in TZM-bl and PBMC-p24 assays.
Virus Clade Tropism TZM-bl assay PBMC assay
m9 m14 m18 m43 m48 b12 2F5 4E10 21.2 m9 m14 m18 m43 m48 b12 2F5 4E10 21.2
92UG_029 A X4 99 56 30 0 0 95 97 91 99 34 0 0 0 0 95 31 9 42
93RW_024 A Dual 18 0 0 0 0 0 93 75 85 85 0 0 0 0 nd 66 0 38
00KE_KER2008 A Dual 85 0 0 0 0 0 85 84 89 0 18 9 0 0 0 42 31 43
99KE_KNH1135 A R5 14 0 11 20 3 100 92 83 73 96 29 32 64 69 95 81 93 75
00KE_KSM 4030 A R5 0 0 0 0 0 0 97 95 91 72 72 49 77 32 31 81 72 85
89BZ_167 B X4 0 84 100 100 0 95 100 99 99 0 61 91 43 12 70 70 60 99
92FR_BXO8 B R5 98 84 83 86 0 85 92 89 98 99 37 46 1 19 70 51 23 99
90US_873 B R5 93 30 18 22 0 100 99 93 96 79 0 45 60 47 93 96 89 99
96TH_NP1538 B R5 69 0 0 0 0 0 61 44 89 94 0 4 18 19 nd 84 39 85
91US_4 B R5 84 0 0 0 6 58 72 73 95 99 68 48 49 46 45 94 81 99
89SM_145 C R5 86 24 9 6 15 0 0 90 83 52 4 8 45 0 nd 0 53 30
01TZ_911 C R5 60 10 0 1 4 5 0 90 90 82 0 4 58 0 nd 0 0 29
98US_MSC5016 C R5 83 70 40 31 0 0 18 98 87 95 0 0 0 0 nd 0 0 0
94IN_20635-4 C R5 99 51 5 0 0 99 0 96 95 90 43 51 54 39 99 8 73 95
00TZ_A125 C R5 16 0 0 0 10 0 0 83 54 42 42 27 50 24 64 39 36 53
00UG_D26830M4 D R5 0 12 0 8 0 4 59 62 98 96 0 33 3 35 66 0 82
93UG_065 D X4 99 21 18 16 6 5 99 90 78 96 67 45 73 28 19 70 62 64
99UG_AO8483M1 D R5 90 87 86 88 10 100 74 59 97 99 36 52 25 0 99 86 62 83
98UG_57128 D R5 94 65 60 65 16 100 1 70 86 92 60 40 59 26 98 10 56 50
00KE_NKU3006 D R5 71 17 0 8 4 67 93 87 49 95 25 55 0 0 nd 74 34 37
90TH_CM235 AE R5 19 24 0 23 24 22 91 80 70 26 0 11 0 0 nd 64 8 53
90TH_CM240 AE R5 95 21 29 30 33 20 90 90 87 20 0 0 18 0 nd 10 37 9
96TH_NI1149 AE R5 14 10 23 14 16 12 3 91 66 87 28 71 72 52 nd 19 47 92
96TH_M02138 AE X4 0 21 33 25 0 16 99 97 90 2 0 0 0 0 nd 23 0 51
90TH_CM244 AE R5 0 24 27 17 37 9 95 89 85 nd nd nd nd nd nd nd nd nd
02CM_1970LE AG R5 10 15 18 12 8 16 99 98 85 93 18 35 14 19 nd 72 0 40
98US_MSC5007 AG R5 91 9 13 15 0 5 74 83 78 87 23 28 52 32 40 93 74 81
02CM_ 0013BBY AG R5 58 9 16 24 5 6 0 90 73 94 51 42 45 66 67 70 66 72
02CM_0015BBY AG R5 25 45 20 9 7 33 95 94 79 68 0 0 12 0 nd 48 11 45
02CM_0014BBY AG R5 36 12 6 5 13 19 19 91 83 93 8 53 1 19 nd 13 26 71
Percentage of virus neutralized 57 23 13 13 0 33 70 97 97 76 21 21 34 10 63 55 41 66
HIV-1-infected patient serum (pool 21.2) was included as a control. Percentage neutralization of viral infection are color coded so that the darker the color, the more
potent the neutralization: a white box indicated ,50% neutralization, a light grey box indicates 50%, percentage neutralization ,90%, and a dark grey box indicates
percentage neutralization .90%. n.d., not done.
doi:10.1371/journal.pone.0044241.t003
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the Env may be due to a steric hindrance. The effect of sCD4 on
m43 binding to recombinant gp140s and membrane-associated
Envs is different. sCD4 weakly inhibited m43 binding to
recombinant gp14089.6 (Fig. 2C), while sCD4 enhanced m43
binding to cleavage-competent gp160JRFL on 293T cells (Fig. 3A).
However, CD4-IgG2 showed inhibitory effect on m43 binding to
Env spikes on H9 cells infected with NL4-3 (X4-tropic) (Fig. 3C
and 3D). This suggests that the m43 epitope on R5- and X4-tropic
viral spikes may be different. We tested m43 binding to cleavage-
competent gp160HxB2 (X4-tropic) on 293T cells by flow cytometry
and observed that sCD4 also inhibited m43 binding to membrane-
associated gp160HxB2 (data not shown). The mechanism for
different effect of CD4 on m43 binding to R5- and X4-tropic viral
Envs remains to be elucidated.
M43 may exist in infected individuals as indicated by a
competition ELISA, in which m43 competed with polyclonal
antibodies purified from immune sera of long-term nonprogressors
for binding to coated Env trimers (data not shown). But the
immune polyclonal antibodies are rich in CD4bs Abs, so the result
was inconclusive. M43 was selected from a combinatorial antibody
library (109 individual clones) by phage display technology, in
which the heavy chain and light chain are randomly paired.
Nevertheless, since m43 has a high affinity (EC50 was below
10 nM for most of recombinant gp140s tested), it is reasonable to
assume that m43 may have the original cognate heavy chain and
light chain pairing [49,50]. This is the first report of a new class of
cross-reactive HIV-1-neutralizing mAbs cotargeting gp120 and
Table 4. Percentage neutralization of IgG1s m43 and VRC01
against a panel of clade B isolates by pseudovirus assay using
JC-10 and JC-53 as indicator cells.
IC50 (mg/
ml) Clade Tropism JC-10 cells JC-53 cells
m43 VRC01 m43 VRC01
Bal B R5 160.83 0.04 17.52 0.03
JRFL B R5 174.67 0.13 .200 0.14
JRCSF B R5 190.47 0.74 .200 1.18
89.6 B Dual 5.67 1.2 28.28 1.24
HxB2 B X4 0.2 0.07 0.2 0.1
VSV-G .100 .10 .100 .10
doi:10.1371/journal.pone.0044241.t004
Figure 4. Percentage neutralization of IgG1 m43 with SHIV viruses. Three clade C (SHIV-1157ipd3N4, SHIV-1157ipEL-p, and SHIV-2873Nip)
and one clade B (SHIV-SF162) SHIV viruses were tested in a PBMC-p27 assay. IgG1 VRC01 was used as positive control, while Fm-6 served as negative
isotype control. The data shown are representative results obtained from two independent experiments.
doi:10.1371/journal.pone.0044241.g004
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Table 5. Percentage neutralization of IgG1s m43, 44, 48 and 4E10 at 50 mg/ml against HIV-1 primary isolates from different clades
in a PBMC-RT assay.
HIV-1 isolate Clade Coreceptor specificity % Inhibition of RT activity (Mean ± SD)
m43 m44* m48 4E10*
92UG029 A X4 62+14 0+5.7 20+14 0+14
92HT594 B X4R5 97+0.1 21+17 65+21 31+8.6
SHIV 89.6p B X4R5 96+0.4 96+0.3 83+12 25+13
92BR025 C R5 66+3.7 72+1.6 68+1.6 58+3.2
97ZA003 C R5 91+2.2 93+1.9 94+1.3 49+12
93IN101 C R5 99+0.0 99+0.1 99+0.1 99+0.1
93MW959 C R5 94+1.0 97+0.5 97+0.6 53+10
92UG001 D X4R5 55+13 35+5.9 38+6.4 29+0.7
93TH073 E R5 95+0.6 97+0.3 96+0.1 68+2.6
93BR029 F R5 94+0.4 93+1.8 76+16 62+12
G3 G R5 94+0.6 93+2.5 93+0.6 57+16
BCF03 O R5 32+9.9 52+20 44+16 34+7.5
Median 94 93 87 51
The percentage inhibition of RT activity in the culture supernatant of HIV-1-infected PBMCs on day 7 is presented as a measure of the antibody inhibitory activity.
*: published data [33].
doi:10.1371/journal.pone.0044241.t005
Figure 5. Effect of sCD4 (top panel) and m43 (low panel) on binding of 17b, 2F5 and 4E10 to JRFL gp160 on 293T cells by flow
cytometry. Curves in red: 2nd Ab (PE-avidin) only; in green: 10 mg/ml biotinylated 17b, or 2F5, or 4E10; in blue: 10 mg/ml sCD4 or m43 in
combination with 10 mg/ml biotinylated 17b, or 2F5, or 4E10; in brown: 50 mg/ml sCD4 or m43 in combination with 10 mg/ml biotinylated 17b, or
2F5, or 4E10.
doi:10.1371/journal.pone.0044241.g005
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gp41. We believe that the results from this study may have
implications for vaccine development.
Strong competition of m43 with CD4bs mAbs for binding to
recombinant Envs and functional Env trimer suggest that m43
neutralizes the virus by blocking the receptor and/or coreceptor
binding to the Env. Unlike sCD4, binding of m43 to functional
Env trimer does not enhance the binding of CD4i mAb 17b and
MPER-specific mAbs 2F5 and 4E10, and does not induce gp120
shedding (Fig. 5 and 6), suggesting that m43 may neutralize the
virus by a second mechanism which is to prevent Env
conformational changes upon binding that is required for virus
entry. There may be a third mechanism for m43 to neutralize the
virus. Since m43 binds to the N-trimer structure, m43 may
neutralize the virus by blocking a prefusion intermediate. We
observed that b12 did not induce shedding in our current assay
using cytoplamic tail truncated gp160JRFL, which is different from
the result previously reported using full-length g160JRFL in the
assay [45].
Conclusions
M43 recognizes a novel neutralizing determinant on HIV-1 Env
that may involve the CD4bs of gp120 and the N-trimer structure
of gp41. M43 epitope is conformational and conserved among
HIV-1 primary isolates from different clades, and exposed on
native Env spikes. M43 may represent a new class of bnAbs that
target both gp120 and gp41 and neutralizes the virus by locking
the native Env conformation, or by blocking the receptor and
coreceptor binding to the Env, or by blocking a prefusion
intermediate, or by two or all of three mechanisms. The novel
neutralizing determinant of m43 and its possible mechanisms of
Figure 6. Effect of m43 binding on JRFL functional Env trimer.
Western blot analysis of Env from the supernatant of 293T cells
transfected with cleavage-competent gp160 JRFLdCT Env plasmid DNA.
HIV-1 gp120 shedding upon binding of ligands, including sCD4, VRC01,
b12, and m43, from the Env trimer on the surface of 293T cells was
evaluated by probing the blot with anti-gp120 human mAb 39F (V3-
specific). Each ligand concentration was 50 mg/ml.
doi:10.1371/journal.pone.0044241.g006
Figure 7. Binding of m43, b12 and VRC01 to cleavage-competent (+) and cleavage-incompetent (2) JRFL and Yu2 gp160s on 293T
cells by flow cytometry. Different concentrations of mAbs used in the assay were indicated. PE conjugated to anti-human IgG, F(ab)2 were used as
secondary antibody for detection.
doi:10.1371/journal.pone.0044241.g007
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neutralization may be useful for HIV-1 vaccine immunogen
design.
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